Company Overview and News

 
Reproductive Health Science targets funding injection

2017-05-31 proactiveinvestors.com.au
Reproductive Health Science (ASX:RHS) has been granted a trading halt by the ASX, pending details of a capital raising.

 
Reproductive Health Science tops ASX % Gainers intra-day

2017-04-13 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

 
Preimplantation Genetic Testing (PGT) Market Size & Forecast By Type, By Application, And Segment Forecasts To 2024

2017-03-13 prnewswire
NEW YORK, March. 13, 2017 /PRNews/ -- l preimplantation genetic testing market was valued at USD 129.3 million in 2015 and is expected to reach a value of USD 221.1 million by 2024, according to a new report by Grand View Research, Inc. Growth in number of offspring born with inherited conditions is a high impact rendering factor for growth of this market. Emergence of preimplantation genetic diagnosis for detection of nearly all genetically inherited conditions enable couples, who are carriers of such conditions, screen their embryos before transferring to uterus and this is the primary driver of this industry.

 
Preimplantation Genetic Testing (PGT) Market Size & Forecast By Type, By Application, And Segment Forecasts To 2024

2016-11-29 prnewswire
LONDON, Nov. 28, 2016 /PRNewswire/ -- The global preimplantation genetic testing market was valued at USD 129.3 million in 2015 and is expected to reach a value of USD 221.1 million by 2024, according to a new report by Grand View Research, Inc. Growth in number of offspring born with inherited conditions is a high impact rendering factor for growth of this market. Emergence of preimplantation genetic diagnosis for detection of nearly all genetically inherited conditions enable couples, who are carriers of such conditions, screen their embryos before transferring to uterus and this is the primary driver of this industry.

 
 
Appendix 3Z

2016-04-22 asx.com.au

 
 
Notice of Meeting & Proxy

2016-04-21 asx.com.au

 
Appendix 3B - Escrow Release

2016-04-18 asx.com.au

 
Reproductive Health Science Ltd's product has success lifting IVF pregnancies

2016-04-08 proactiveinvestors.com.au
Reproductive Health Science Ltd (ASX:RHS) is a developer of advanced single cell genomic technologies with a focus on improving health and research outcomes.

 
Release of Shares from Escrow

2016-04-04 asx.com.au

 
Annual Report 2015

2016-03-10 asx.com.au

 
Appendix 4G

2016-03-10 asx.com.au

 

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...